Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical and Pharmacokinetic Equivalence of a Biosimilar Adalimumab in Rheumatoid Arthritis Patients: A Phase III Trial
*Corresponding Author: Kudirat Taofeek Tope, Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and, Pharmacy, University of Rwanda, Rwanda, Email: taofeektope78@gmail.comReceived Date: Jun 02, 2025 / Published Date: Jun 30, 2025
Citation: Kudirat TT (2025) Clinical and Pharmacokinetic Equivalence of a Biosimilar Adalimumab in Rheumatoid Arthritis Patients: A Phase III Trial. Clin Pharmacol Biopharm, 14: 583.
Copyright: © 2025 Kudirat TT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
To read the full article Peer-reviewed Article PDF 
